Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)

NCT04084769 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

570

Enrollment

INDUSTRY

Sponsor class

Conditions

Meningococcal Immunisation (Healthy Volunteers)

Interventions

BIOLOGICAL: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine
BIOLOGICAL: Meningococcal Group B vaccine (Trumenba®)
BIOLOGICAL: Meningococcal group B vaccine (Bexsero®)

Sponsor

Sanofi Pasteur, a Sanofi Company